Media coverage about Intrexon (NYSE:XON) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intrexon earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.6564223928639 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of analysts have issued reports on XON shares. Zacks Investment Research downgraded Intrexon from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Northland Securities reaffirmed a “buy” rating and set a $21.00 price target on shares of Intrexon in a report on Friday, November 10th. Stifel Nicolaus lifted their price target on Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Bank of America decreased their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Finally, Griffin Securities reaffirmed a “buy” rating and set a $55.00 price target on shares of Intrexon in a report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $38.50.

Shares of Intrexon (NYSE XON) opened at $14.71 on Monday. The stock has a market capitalization of $1,780.00, a PE ratio of -13.13 and a beta of 1.33. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $26.99.

Intrexon (NYSE:XON) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%. sell-side analysts predict that Intrexon will post -1.06 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.